Personalized mRNA cancer vaccines are no longer theoretical. In early 2026, BioNTech published data showing that 11 of 14 triple-negative breast cancer patients who received their personalized vaccine had not relapsed after more than six years. Moderna's partnership with Merck on their V940 vaccine showed a 49% reduction in cancer recurrence for advanced melanoma patients at five years.
The process starts with sequencing the patient's tumor and comparing it against their healthy genome. This comparison reveals the mutations unique to that person's cancer. AI tools then predict which of those mutations produce proteins that the patient's immune system can recognize — based on their specific MHC profile. Finally, an mRNA vaccine is designed that teaches the immune system to attack cells displaying those specific proteins.
Clinical trials are now underway for personalized mRNA vaccines targeting melanoma, pancreatic cancer, colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer. Over 120 clinical trials involving RNA-based cancer vaccines are currently active globally, with first commercial approvals expected by 2029.
One of the biggest challenges has been production time. Early personalized vaccines took nine weeks to manufacture. That timeline has been reduced to under four weeks, and Houston Methodist recently demonstrated the ability to design, manufacture, and deploy personalized mRNA vaccines entirely within an academic medical center setting.
Every one of these treatments starts with the same requirement: the patient's complete genome and MHC profile. Having both pre-stored means treatment can begin the moment a diagnosis happens, without waiting weeks for sequencing. As these vaccines move from clinical trials to standard care, genome readiness will shift from optional to essential.
Related: How One Man Used AI to Save His Dog · How AI Is Accelerating Cancer Vaccines · View Pricing
Ready to secure your genome?
Join the Waitlist